Top Story

Adjuvant FOLFOX extended DFS in locally advanced rectal cancer

October 2, 2014

The addition of oxiliplatin to fluorouracil and leucovorin extended DFS among patients with locally advanced rectal cancer who underwent preoperative chemotherapy and total mesorectal excision, according to results of a randomized phase 2 study.

Adjuvant chemotherapy for rectal cancer is controversial, particularly among patients who underwent preoperative chemotherapy. Adjuvant chemotherapy with fluorouracil and leucovorin is commonly used.

Potential liver repair drug CF102 issued US patent

September 30, 2014
Can-Fite BioPharma received a US patent for CF102, a drug under development to repair liver cells and function in patients with hepatocellular carcinoma, according to a…
Meeting News Coverage

Safety, efficacy of sorafenib exposure inconsistent in HCC, RCC patients

September 29, 2014
There was no apparent relationship between exposure to sorafenib and safety and efficacy among patients with hepatocellular carcinoma or renal cell carcinoma, according…
Meeting News Coverage

Patients with advanced pancreatic NET achieved 44-month OS with Afinitor

September 29, 2014
Results from a phase 3 trial presented at the European Society for Medical Oncology 2014 Congress in Madrid showed overall survival of more than 3.5 years in patients…
CME
figure

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates

This activity is supported by an educational grant from Merck & Co., Inc.

Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »
CME CNE
figure

Treatment Decision-Making through the Spectrum of MDS: Case 1 Low Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain MDS…
More »

Filter By:

In the Journals

Adjuvant FOLFOX extended DFS in locally advanced rectal cancer

October 2, 2014
The addition of oxiliplatin to fluorouracil and leucovorin extended DFS among patients with locally advanced rectal cancer who underwent preoperative…

Potential liver repair drug CF102 issued US patent

September 30, 2014
Can-Fite BioPharma received a US patent for CF102, a drug under development to repair liver cells and function in patients with hepatocellular…
Meeting News Coverage

Safety, efficacy of sorafenib exposure inconsistent in HCC, RCC patients

September 29, 2014
There was no apparent relationship between exposure to sorafenib and safety and efficacy among patients with hepatocellular carcinoma or renal cell…
Meeting News Coverage

Patients with advanced pancreatic NET achieved 44-month OS with Afinitor

September 29, 2014
Results from a phase 3 trial presented at the European Society for Medical Oncology 2014 Congress in Madrid showed overall survival of more than 3.5…
Meeting News Coverage

Obesity, inflammation during adolescence increased colorectal cancer later in life

September 29, 2014
Adolescent males who were obese or had blood markers that suggested high levels of inflammation demonstrated a higher risk for colorectal cancer…
In the Journals

HCC patients in longer waiting time regions for LT showed better overall survival

September 26, 2014
Candidates for liver transplant with hepatocellular carcinoma listed in the long waiting time regions had higher overall survival rates compared with…
figure In the Journals

Provider-based research networks may reduce racial disparities in colorectal cancer therapy

September 26, 2014
African-American patients with stage III colon cancer were more likely to receive early access to innovative treatment at provider-based research…
FDA News

FDA grants orphan drug status to RX-3117 for pancreatic cancer

September 25, 2014
Rexahn Pharmaceuticals recently announced that the FDA has granted orphan drug designation to its cancer-specific nucleoside analog, RX-3117, for the…
figure Cover Story Publication Exclusive

Quest for clinically meaningful PFS benefit an ‘imperfect science’

HemOnc Today, September 25, 2014
Small improvements in study endpoints often serve as the foundation for drug approvals.However, a small but vocal segment of the hematology and…
figure Editorial Publication Exclusive

I’d like to agree with you … but then we’d both be wrong!

HemOnc Today, September 25, 2014
Derek Raghavan, MD, PhD
I sometimes fear that I am a natural curmudgeon, or at the very least a true cynic.If you have read my recent editorials and op-eds, it may seem I…
More Headlines »